New York City, New York May 5, 2020 (Issuewire.com) - Trusted Business Insights presents an updated and Latest Study on "Human Platelet Lysate Market". The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Protective Riding Gear Market market during the forecast period (2019-2029).
It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.
Human platelet lysate (HPL) is a non-animal derived cell culture growth supplement obtained from blood platelets after freezing and thawing. HPL contains abundant growth factors and cytokines necessary for cell growth and proliferation. Platelet lysate can be used as a source of growth factors to replace bovine serum in the cell culture medium. Replacing bovine serum with HPL allows expansion and clinical grade production of functional mesenchymal stromal cells by removing the risk of xenogeneic immune reactions and transmission of bovine prion and viral pathogens.
The global Human Platelet Lysate market is valued at 129.34 million US$ in 2017 growing at a CAGR of 26.8% during 2019-2025.
The demand of Human Platelet Lysate for Clinical applications accounted for US$87.51 Mn of total market value in 2017.
Snapshot of Porter’s Five Forces Analysis for the current Human Platelet Lysate market.
Supplier Power: High
"Limited number of suppliers that can meet the high-quality standards set for human platelet lysate manufacturing"
Threat of Substitution: Low
"Prices of human platelet lysate are expected to be stable hence fewer chances of getting substituted"
Buyer Power: Low
"Limited number of human platelet lysate manufacturers have the ability to meet a high degree of customization requirements of the large buyers"
Threat of New Entry: Medium
"Rising demand for human platelet lysate products across both developed and developing countries"
Competitive Rivalry: Moderate
"The degree of competition is moderate as the manufacturers are offering similar product categories with limited differentiating attributes. Many of the market players are looking for their own arrangements of raw materials. This may lead to reduced pricing pressure during the forecast period."
Top Level Analysis of Human Platelet Lysate Market:
The US FDA is moving towards adopting European guidelines requiring that bovine materials be removed from culturing media for any therapeutic product containing cultured cells, thus making human platelet lysate an attractive alternative to the production and manufacturing processes which is anticipated to fuel the demand of human platelet lysate during the forecast period.
Traditionally, the fetal bovine serum is supplemented in basic research and in most clinical trials. Within the past years, many laboratories adapted their culture conditions to human platelet lysate (hPL), which further stimulates the proliferation and expansion of MSCs. Particularly with regard to clinical application, human alternatives
In 2016, the market size of the Heparin-free Platelet Lysate market was USD $45.96 Million and the market size of Platelet Lysate with Heparin was USD $47.76 Million with a total market value of USD $93.72 Million. Clinical application and Research Application accounted for USD $63.56 Million and USD $30.16 Million respectively.
Additionally, in terms of volume(liters), Heparin-free Platelet Lysate market demand was of 19512 liters, approximately 5154 US gallons and that of Platelet Lysate with Heparin was 20445 liters, approximately 5400 US Gallons (Total of 39957 liters, 10554 US Gallon)
North America Human Platelet Lysate market accounted for 44% of market share, followed by Europe at 26%. APAC, Latin America, Middle East, and Africa Human platelet size was 19%, 6%, and 5% respectively.
Bifurcation of demand by End-User Industries
Contract Research Organizations - USD $31.26 Million - 12629 (Litres)
Biopharmaceutical Companies - USD $24.74 Million - 9997 (Litres)
Academic & Research Institutes - USD $19.55 Million - 7898 (Litres)
Cell Therapy Manufacturers - USD $18.18 Million - 7343 (Litres)
This report focuses on Human Platelet Lysate volume and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Human Platelet Lysate market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, China, and Japan.
This market research study provides detailed qualitative and quantitative analyses of the global Human Platelet Lysate Market. Additionally, the report provides a comprehensive review of the major market drivers, restraints, opportunities in the global Human Platelet Lysate Market.
At the company level, this report focuses on the production capacity, ex-factory price, revenue, and market share for each manufacturer covered in this report.
The following manufacturers of Platelet Lysate are covered
Mill Creek Life Sciences
Merck & Co., Inc
STEMCELL Technologies Inc
AventaCell BioMedical
Compass Biomedical, Inc
Macopharma SA
Trinova Biochem GmbH
PL BioScience GmbH
Cook Regentec
Cambium Medical Technologies
Life Science Group
Zen-Bio, Inc.
Segment by Regions
North America
APAC
EMEA
LATAM
Segment by Type
Heparin
Heparin free
Segment by Application
Bio-pharmaceutical companies
Contract research organizations
Academic & research institutes
Pharmaceutical companies
Others
For further reading and requesting your free copy of the report please click here
Media Contact
Trusted Business Insights shelly.arnold@trustedbusinessinsights.com +1-646-568-9797 https://www.trustedbusinessinsights.com/
